All In Biotech

NDA 217865 · Italfarmaco Spa

Duvyzat

Givinostat Hydrochloride · Oral · Histone Deacetylase Inhibitor

NovelPriority reviewOrphan

CDER novel approval, Mar 21, 2024: To treat Duchenne muscular dystrophy in individuals aged 6 years and older

Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Mar 21, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

25

4 Phase 3, 4 recruiting

FAERS reports

635

172 serious, 17 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 1, 2026.

DUVYZAT is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. DUVYZAT is a histone deacetylase inhibitor indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. ( 1 )

Mechanism: DUVYZAT is a histone deacetylase inhibitor. The precise mechanism by which DUVYZAT exerts its effect in patients with DMD is unknown.

Therapeutic areas: Neurology · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 21, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
  • DUVYZAT · GIVINOSTAT HYDROCHLORIDE EQ 8.86MG BASE/ML · SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Givinostat" as an intervention, any sponsor and status, largest first.

All 25 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • platelet count decreased132
  • diarrhoea85
  • blood triglycerides increased60
  • abdominal discomfort46
  • vomiting45
  • nausea44
  • weight increased40
  • thrombocytopenia39
  • product dose omission issue38
  • off label use27
  • pyrexia27
  • abdominal pain upper25

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20212
202449
2025374
2026210

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Duvyzat (Givinostat Hydrochloride)

2024 spending

$2.0M

Beneficiaries

n/a

27 claims

Per beneficiary

n/a

$268.72 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$1,956,267

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: Italfarmaco Spa

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.